Author

S. E. Guimond

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 3 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

J. E. Turnbull· 4 shared M. A. Skidmore· 4 shared C. J. Mycroft-West· 3 shared E. A. Yates· 3 shared D. Su· 2 shared I. Bagdonaite· 2 shared M. A. Lima· 2 shared Y.-H. Chen· 2 shared

Activity by Year

2020-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersBiochemistry

J. E. Turnbull

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

The hyperlipidaemic drug fenofibrate significantly reduces infection by SARS-CoV-2 in cell culture models

S. P. Davies, C. J. Mycroft-West, I. Pagani, H. J. Hill, Y.-H. Chen, R. T. Karlsson, I. Bagdonaite, S. E. Guimond, Z. Stamataki, M. A. Lima, J. E. Turnbull, Z. Yang, E. E. Vicenzi, M. A. Skidmore, F. Khanim, A. Richardson

This study shows fenofibrate and its metabolite fenofibric acid reduce SARS-CoV-2 infection in cell culture by up to 70% at clinically achievable concentrations.

bioRxiv · Jan 10, 2021Pharmacology & Toxicology

Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 By Disrupting The Spike-ACE2 interaction

S. E. Guimond, C. J. Mycroft-West, N. S. Gandhi, J. A. Tree, T. T. Le, C. M. Spalluto, M. V. Humbert, K. R. Buttigieg, N. Coombes, M. J. Elmore, K. Nystrom, J. Said, Y. X. Setoh, A. Amarilla, N. Modhiran, , J. E. Turnbull

This paper shows that pixatimod inhibits SARS-CoV-2 by disrupting the Spike-ACE2 interaction, demonstrating its potential as an anti-COVID-19 therapeutic.

bioRxiv · Jun 24, 2020Microbiology

The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding.

C. J. Mycroft-West, D. Su, S. Elli, Y. Li, S. E. Guimond, G. J. Miller, J. E. Turnbull, E. A. Yates, M. Guerrini, D. G. Fernig, M. Andrade de Lima, M. A. Skidmore

The paper shows that SARS-CoV-2 Spike S1 RBD undergoes a conformational change when bound to heparin, suggesting potential for heparin as a therapeutic.

bioRxiv · Feb 29, 2020 · PreprintBiochemistry

High sensitivity (zeptomole) detection of BODIPY heparan sulfate (HS) disaccharides by ion-paired RP-HPLC and LIF detection enables analysis of HS from mosquito midguts.

M. L. Maciej-Hulme, A. C. Leprince, A. Lavin, S. E. Guimond, J. E. Turnbull, J. Pelletier, E. A. Yates, A. K. Powell, M. A. Skidmore

This paper develops a highly sensitive method to detect BODIPY-labeled HS disaccharides, enabling analysis of HS from small biological samples like mosquito midguts.

bioRxiv · Jan 21, 2020 · PreprintBiochemistry